H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Allogene Therapeutics (NASDAQ:ALLO) Inc on Friday, setting a price target of $43, which is approximately 81.21% above the present share price of $23.73.
Burns expects Allogene Therapeutics Inc to post earnings per share (EPS) of -$0.25 for the third quarter of 2021.
The current consensus among 11 TipRanks analysts is for a Strong Buy rating of shares in Allogene Therapeutics, with an average price target of $47.33.
The analysts price targets range from a high of $55 to a low of $39.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $38.35 million and a net profit of -$33.2 million. The company's market cap is $3.36 billion.
According to TipRanks.com, H.C. Wainwright analyst Robert Burns is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 4.2% and a 38.42% success rate.
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.